Oppenheimer initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $7 price target The firm said the rating is based on its conviction for lead asset OV329 to address epilepsy disorders with validating clinical data. OV329 modulates GABA to calm seizures, and Oppenheimer sees a $1B+ potential market opportunity, the firm tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID: